TxA 2 exerts its action on platelets by reducing their intracellular cyclic adenosine monophosphate (cAMP) levels: this stimulates granule content release. TxA 2 is also a potent vasoconstrictor: its actions antagonize those of prostacyclin produced by the vascular endothelium.